Results 181 to 190 of about 732,506 (308)
Artificially Engineered Synthetic Biomarkers Revolutionizing Early Diagnosis of Diseases. [PDF]
Wang A +8 more
europepmc +1 more source
Evaluation of circulating tumor DNA as a biomarker for gynecological tumors
Kang-Sheng Liu +5 more
openaire +3 more sources
This study highlights how cervical carcinoma progression is shaped by immune–tumor interactions within the TME. M2‐TAM infiltration, regulated through STAT3/NF‐κB and linked to CXCL12–CXCR4, promotes immune suppression, angiogenesis, and poor survival.
George A. Lira +11 more
wiley +1 more source
Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology. [PDF]
Brown JR, Sonpavde G.
europepmc +1 more source
Biofabrication aims at providing innovative technologies and tools for the fabrication of tissue‐like constructs for tissue engineering and regenerative medicine applications. By integrating multiple biofabrication technologies, such as 3D (bio) printing with fiber fabrication methods, it would be more realistic to reconstruct native tissue's ...
Waseem Kitana +2 more
wiley +1 more source
Translational role of molecular biomarkers in developing targeted therapies for central nervous system tumors. [PDF]
Rathored J +3 more
europepmc +1 more source
Platinum‐Copper bimetallic nanoparticles may evolve depending on their synthesis under tumor microenvironment conditions and play a dual role as chemotherapeutic agents after releasing Cu ions and as near infrared photothermal agents with the Pt‐rich remaining frames.
Jose I. Garcia‐Peiro +7 more
wiley +1 more source
CXCL12 deficiency promotes colorectal cancer progression and reduces anti-PD-L1 immunotherapy efficacy through MDSC regulation. [PDF]
Zhao H +11 more
europepmc +1 more source
Porous silicon nanoparticles (PSiNPs) reprogram macrophage endocytosis of manganese@albumin‐based TLR4 nanoagonists, driving TRIF‐biased TLR4 signaling, eliciting robust proinflammatory responses, and potentiating macrophage‐mediated immunotherapeutic effects against NSCLC.
Xiaomei Zhang +9 more
wiley +1 more source
Bridging Discovery and Treatment: Cancer Biomarker. [PDF]
Liu H, Karsidag I, Golin R, Wu G.
europepmc +1 more source

